Dec 17, 2009 - Unigene Laboratories, Inc. (OTCBB: UGNE) announced that it has selected a lead peptide compound, designated UGP281, from its obesity program for development. In a short-term study reported at the Keystone Symposium Conference on "Obesity: Novel Aspects of the Regulation of Body Weight" last January, a previously developed compound, orally-administered UGL269, reduced food intake in dogs by up to 50% and correspondingly reduced body weight. Subsequent studies by Unigene have led to the development of UGP281, a peptide modeled after naturally-occurring hormones which is significantly more potent than UGL269 and achieves the same reduction in food consumption at a lower dose. Importantly, in comparative animal studies at the same dose, UGP281 was at least 3-fold more effective in reducing food consumption than certain other peptide compounds that are currently in later-stage clinical development by third parties for accelerated weight loss. In addition, there were no overt signs of toxicity. The pronounced reductions in feeding behavior, as well as the weight of the animals after daily administration of this peptide, persisted over several weeks of dosing. The peptide has the additional advantages that it can be delivered orally using Unigene's Enteripep(R) technology and manufactured using Unigene's Secrapep(R) technology... Unigene's Press Release -
Monday, December 21, 2009
Unigene : Promising Preclinical Results in Its Obesity Peptide Program
Dec 17, 2009 - Unigene Laboratories, Inc. (OTCBB: UGNE) announced that it has selected a lead peptide compound, designated UGP281, from its obesity program for development. In a short-term study reported at the Keystone Symposium Conference on "Obesity: Novel Aspects of the Regulation of Body Weight" last January, a previously developed compound, orally-administered UGL269, reduced food intake in dogs by up to 50% and correspondingly reduced body weight. Subsequent studies by Unigene have led to the development of UGP281, a peptide modeled after naturally-occurring hormones which is significantly more potent than UGL269 and achieves the same reduction in food consumption at a lower dose. Importantly, in comparative animal studies at the same dose, UGP281 was at least 3-fold more effective in reducing food consumption than certain other peptide compounds that are currently in later-stage clinical development by third parties for accelerated weight loss. In addition, there were no overt signs of toxicity. The pronounced reductions in feeding behavior, as well as the weight of the animals after daily administration of this peptide, persisted over several weeks of dosing. The peptide has the additional advantages that it can be delivered orally using Unigene's Enteripep(R) technology and manufactured using Unigene's Secrapep(R) technology... Unigene's Press Release -
Subscribe to:
Posts (Atom)
